667 A phase 1, multiple-dose study to evaluate the safety and tolerability of XmAb®819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (RCC) | Zendy

AI Assistant Blog Pricing

667 A phase 1, multiple-dose study to evaluate the safety and tolerability of XmAb®819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (RCC)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.